Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial.
Coghill DR, Banaschewski T, Lecendreux M, Soutullo C, Zuddas A, Adeyi B, Sorooshian S. Coghill DR, et al. Among authors: adeyi b. Neuropsychiatr Dis Treat. 2014 Oct 29;10:2039-47. doi: 10.2147/NDT.S68273. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 25378930 Free PMC article.
Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Findling RL. Turgay A, et al. Among authors: adeyi b. J Child Adolesc Psychopharmacol. 2010 Dec;20(6):503-11. doi: 10.1089/cap.2009.0110. J Child Adolesc Psychopharmacol. 2010. PMID: 21186969 Free PMC article. Clinical Trial.
Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T, Dirks B, Adeyi B, Scheckner B. Babcock T, et al. Among authors: adeyi b. BMC Pharmacol Toxicol. 2012 Dec 19;13:18. doi: 10.1186/2050-6511-13-18. BMC Pharmacol Toxicol. 2012. PMID: 23254273 Free PMC article. Clinical Trial.
Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
Weisler R, Ginsberg L, Dirks B, Deas P, Adeyi B, Adler LA. Weisler R, et al. Among authors: adeyi b. J Atten Disord. 2017 Dec;21(14):1198-1207. doi: 10.1177/1087054713518242. Epub 2014 Jan 24. J Atten Disord. 2017. PMID: 24464328 Clinical Trial.
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P, Häge A, Coghill DR, Caballero B, Adeyi B, Anderson CS, Sikirica V, Cardo E. Nagy P, et al. Among authors: adeyi b. Eur Child Adolesc Psychiatry. 2016 Feb;25(2):141-9. doi: 10.1007/s00787-015-0718-0. Epub 2015 May 22. Eur Child Adolesc Psychiatry. 2016. PMID: 25999292 Free PMC article. Clinical Trial.
29 results